![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RG Dickinson, RC Harland, AM Ilias, RM Rodgers, SN Kaufman, RK Lynn and N Gerber
A specific gas chromatographic assay has been developed for measurement of valproic acid (VPA) and its major conjugated metabolites. In rats given single intravenous doses, the decline in blood concentration of VPA was dose-dependent and followed first-order kinetics only at the lowest dose. The time required for the maximum concentration of VPA, after completion of the brief distribution phase, to decline by 50% was 11.7, 41 and 125 min at doses of 15, 150 and 600 mg of NaVPA per kg, respectively. A secondary increase in drug concentration, abolished by exteriorization of the bile, was observed in all intact rats with all doses. Some 45 to 55% of the dose appeared in the bile in 5 hr as VPA glucuronide. Urinary excretion of VPA glucuronide in intact animals accounted for 23 and 51% of the 15 and 150 mg/kg doses, respectively. Tissue distribution studies in rats sacrificed 20 and 90 min after dosage with [14C] NaVPA (150 mg/kg) showed that the drug concentration was highest in blood, moderate in liver, kidney, heart and lung and low in brain, fat, testis and skeletal muscle. During this interval the drug concentration declined in all tissues, whereas the total conjugated metabolites in the small intestine increased from 7 to 28% of the administered dose. The large intestine contained 30 times as much free drug as conjugate. Reabsorption of free VPA, released by hydrolysis of conjugate in the large bowel, accounted for the secondary rise in concentration of VPA observed in blood after single doses. The major urinary metabolites, VPA-glucuronide and 2-n-propylgutaric acid, were identified by gas chromatography/chemical ionization mass spectrometry. Sodium VPA caused a dose-dependent stimulation of bile flow, the magnitude and duration of which closely followed the blood concentration of VPA.
This article has been cited by other articles:
|
|
 |
|
  I. Spriet, J. Goyens, W. Meersseman, A. Wilmer, L. Willems, and W. V. Paesschen Interaction Between Valproate and Meropenem: A Retrospective Study Ann. Pharmacother., July 1, 2007; 41(7): 1130 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Spriet, W. Meersseman, E. De Troy, A. Wilmer, M. Casteels, and L. Willems Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus Am. J. Health Syst. Pharm., January 1, 2007; 64(1): 54 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Coves-Orts, J. Borras-Blasco, A. Navarro-Ruiz, A. Murcia-Lopez, and F. Palacios-Ortega Acute Seizures Due to a Probable Interaction Between Valproic Acid and Meropenem Ann. Pharmacother., March 1, 2005; 39(3): 533 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. E. Wright and R. G. Dickinson Abolition of Valproate-Derived Choleresis in the Mrp2 Transporter-Deficient Rat J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 584 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Grillo, G. Chiellini, M. Tonelli, and L. Z. Benet Effect of alpha -Fluorination of Valproic Acid on Valproyl-S-Acyl-CoA Formation in Vivo in Rats Drug Metab. Dispos., September 1, 2001; 29(9): 1210 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wong, D. W. Rurak, S. Kumar, E. Kwan, F. S. Abbott, and K. W. Riggs Dose-Dependent Pharmacokinetics and Metabolism of Valproic Acid in Newborn Lambs and Adult Sheep Drug Metab. Dispos., April 13, 2001; 29(5): 664 - 675. [Abstract] [Full Text]
|
|
|
|
|
|
E. S. Ward, G. M. Pollack, and K. L. R. Brouwer Probenecid-Associated Alterations in Valproic Acid Pharmacokinetics in Rats: Can in Vivo Disposition of Valproate Glucuronide Be Predicted from in Vitro Formation Data? Drug Metab. Dispos., April 13, 2001; 28(12): 1433 - 1439. [Abstract] [Full Text]
|
|
|
|
|
|
S. Kumar, H. Wong, S. A. Yeung, K. W. Riggs, F. S. Abbott, and D. W. Rurak Disposition of Valproic Acid in Maternal, Fetal, and Newborn Sheep II: Metabolism and Renal Elimination Drug Metab. Dispos., July 1, 2000; 28(7): 857 - 864. [Abstract] [Full Text]
|
|
|
|
|
|
K. Matsui, M. Mishima, Y. Nagai, T. Yuzuriha, and T. Yoshimura Absorption, Distribution, Metabolism, and Excretion of Donepezil (Aricept) after a Single Oral Administration to Rat Drug Metab. Dispos., December 1, 1999; 27(12): 1406 - 1414. [Abstract] [Full Text]
|
|
|
|
|
|
N. Yamamura, K. Imura, H. Naganuma, and K. Nishimura Panipenem, A Carbapenem Antibiotic, Enhances the Glucuronidation of Intravenously Administered Valproic Acid in Rats Drug Metab. Dispos., June 1, 1999; 27(6): 724 - 730. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Kojima, M. Nadai, K. Kitaichi, L. Wang, T. Nabeshima, and T. Hasegawa Possible Mechanism by Which the Carbapenem Antibiotic Panipenem Decreases the Concentration of Valproic Acid in Plasma in Rats Antimicrob. Agents Chemother., December 1, 1998; 42(12): 3136 - 3140. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
